Biocryst Pharmaceuticals Inc.
NASDAQ:BCRX 4:00:00 PM EDT
| Market Cap (Intraday) | 2.49B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $12.80 |
| 50-Day MA | $13.05 |
| 200-Day MA | $12.75 |
Biocryst Pharmaceuticals Inc. Stock, NASDAQ:BCRX
4505 Emperor Boulevard, Suite 200, Durham, North Carolina 27703-8457
United States of America
Phone: +1.919.859.1302
Number of Employees: 358
Description
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.